Cullinan Therapeutics, Inc. (CGEM)
(Delayed Data from NSDQ)
$16.34 USD
+0.24 (1.49%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $16.32 -0.02 (-0.12%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
CGEM 16.34 +0.24(1.49%)
Will CGEM be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for CGEM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CGEM
Ocuphire (OCUP) to Report Q4 Earnings: What's in the Cards?
Puma Biotechnology (PBYI) to Report Q4 Earnings: What's in Store?
CGEM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Avalo (AVTX) to Report Q4 Earnings: What's in the Cards?
Sarepta (SRPT) to Report Q4 Earnings: Will It Beat Estimates?
Perrigo (PRGO) to Report Q4 Earnings: What's in the Cards?
Other News for CGEM
Cullinan Management (CGEM) Gets a Buy from Wedbush
Buy Rating Affirmed for Cullinan Management Amid Promising Clinical Trials and Market Potential
Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus
Cullinan Management Advances SLE Treatment with CLN-978 Trial
3 Best Stocks to Buy Now, 9/17/2024, According to Top Analysts